Literature DB >> 28640443

Pathophysiology of Aortic Stenosis and Mitral Regurgitation.

Gianluca L Perrucci1,2, Marco Zanobini1, Paola Gripari1, Paola Songia1, Bayan Alshaikh3, Elena Tremoli1, Paolo Poggio1.   

Abstract

The global impact of the spectrum of valve diseases is a crucial, fast-growing, and underrecognized health problem. The most prevalent valve diseases, requiring surgical intervention, are represented by calcific and degenerative processes occurring in heart valves, in particular, aortic and mitral valve. Due to the increasing elderly population, these pathologies will gain weight in the global health burden. The two most common valve diseases are aortic valve stenosis (AVS) and mitral valve regurgitation (MR). AVS is the most commonly encountered valve disease nowadays and affects almost 5% of elderly population. In particular, AVS poses a great challenge due to the multiple comorbidities and frailty of this patient subset. MR is also a common valve pathology and has an estimated prevalence of 3% in the general population, affecting more than 176 million people worldwide. This review will focus on pathophysiological changes in both these valve diseases, starting from the description of the anatomical aspects of normal valve, highlighting all the main cellular and molecular features involved in the pathological progression and cardiac consequences. This review also evaluates the main approaches in clinical management of these valve diseases, taking into account of the main published clinical guidelines. © 2017 American Physiological Society. Compr Physiol 7:799-818, 2017.
Copyright © 2017 John Wiley & Sons, Inc.

Entities:  

Mesh:

Year:  2017        PMID: 28640443     DOI: 10.1002/cphy.c160020

Source DB:  PubMed          Journal:  Compr Physiol        ISSN: 2040-4603            Impact factor:   9.090


  7 in total

Review 1.  Endothelial-to-Mesenchymal Transition in Calcific Aortic Valve Disease.

Authors:  Xiaochun Ma; Diming Zhao; Peidong Yuan; Jinzhang Li; Yan Yun; Yuqi Cui; Tao Zhang; Jiwei Ma; Liangong Sun; Huibo Ma; Yuman Zhang; Haizhou Zhang; Wenlong Zhang; Junjie Huang; Chengwei Zou; Zhengjun Wang
Journal:  Acta Cardiol Sin       Date:  2020-05       Impact factor: 2.672

2.  Purinergic Receptor P2Y2 Stimulation Averts Aortic Valve Interstitial Cell Calcification and Myofibroblastic Activation.

Authors:  Donato Moschetta; Enrico Di Maria; Vincenza Valerio; Ilaria Massaiu; Michele Bozzi; Paola Songia; Yuri D'alessandra; Veronika A Myasoedova; Paolo Poggio
Journal:  Biomedicines       Date:  2022-02-16

3.  Sex-Specific Cell Types and Molecular Pathways Indicate Fibro-Calcific Aortic Valve Stenosis.

Authors:  Veronika A Myasoedova; Ilaria Massaiu; Donato Moschetta; Mattia Chiesa; Paola Songia; Vincenza Valerio; Valentina Alfieri; Romain Capoulade; Daniela Trabattoni; Daniele Andreini; Elvira Mass; Valentina Parisi; Paolo Poggio
Journal:  Front Immunol       Date:  2022-02-24       Impact factor: 7.561

4.  Prioritization of Candidate Biomarkers for Degenerative Aortic Stenosis through a Systems Biology-Based In-Silico Approach.

Authors:  Nerea Corbacho-Alonso; Tamara Sastre-Oliva; Cecilia Corros; Teresa Tejerina; Jorge Solis; Luis F López-Almodovar; Luis R Padial; Laura Mourino-Alvarez; Maria G Barderas
Journal:  J Pers Med       Date:  2022-04-15

Review 5.  Current Evidence and Future Perspectives on Pharmacological Treatment of Calcific Aortic Valve Stenosis.

Authors:  Maristella Donato; Nicola Ferri; Maria Giovanna Lupo; Elisabetta Faggin; Marcello Rattazzi
Journal:  Int J Mol Sci       Date:  2020-11-04       Impact factor: 5.923

6.  Combined Mitral and Aortic Valve Surgery: 17-year Experience in a Single Center.

Authors:  Annastiina Husso; Teemu Riekkinen; Aino Rissanen; Juho Ollila; Antti Valtola
Journal:  Scand J Surg       Date:  2021-01-18       Impact factor: 2.360

7.  Aggravation of functional mitral regurgitation on left ventricle stiffness in type 2 diabetes mellitus patients evaluated by CMR tissue tracking.

Authors:  Yi Zhang; Wei-Feng Yan; Li Jiang; Meng-Ting Shen; Yuan Li; Shan Huang; Ke Shi; Zhi-Gang Yang
Journal:  Cardiovasc Diabetol       Date:  2021-07-31       Impact factor: 9.951

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.